The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 11, 1990

Filed:

Jul. 06, 1987
Applicant:
Inventors:

Michael J Bjorn, Hercules, CA (US);

Arthur E Frankel, Durham, NC (US);

Walter J Laird, Pinole, CA (US);

David B Ring, Redwood City, CA (US);

Jeffrey L Winkelhake, Alameda, CA (US);

Assignee:

Cetus Corporation, Emeryville, CA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K / ; A61K / ;
U.S. Cl.
CPC ...
530389 ; 530388 ; 530387 ; 530390 ; 530391 ; 530808 ; 424 8591 ; 514885 ;
Abstract

Immunotoxins comprising a cytotoxic moiety and an antigen binding portion selected from the group consisting of Fab, Fab' and F(ab').sub.2 fragments of a monoclonal antibody, which binds to human ovarian cancer tissue, having one of the following capabilities are claimed: cytotoxic ID.sub.50 of about 10 nM or less against human ovarian cancer cells, retardation of human ovarian cancer tumor growth in mammals, or extension of survival of a mammal carrying a human ovarian cancer tumor. Antigens or epitopes to which the monoclonal antibodies bind are identified and characterize the immunotoxins. In a preferred embodiment an immunotoxin comprising at least an antigen binding portion of a monoclonal antibody, which binds to human transferrin receptor, but does not block binding of transferrin to the receptor, is described and claimed. Immunotoxin comprising the F(ab').sub.2 region of the antitransferrin monoclonal antibody are also claimed. Methods of killing human ovarian cancer cells, retarding the growth of human ovarian cancer tumors in mammals and extending the survial of mammals carrying human ovarian cancer tumors are claimed.


Find Patent Forward Citations

Loading…